Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test

About Cancer Care Ontario’s recommendations for prostate-specific antigen (PSA) screening

1. What does Cancer Care Ontario recommend for prostate cancer screening?

Systematic reviews of randomized controlled trials of prostate cancer screening using the prostate-specific antigen (PSA) test have shown inconsistent results; some evidence have shown no effect of PSA testing on prostate-cancer mortality while others have shown a small reduction in prostate-cancer mortality. Harms associated with screening, including over-diagnosis and over-treatment, are common. Therefore, Cancer Care Ontario does not support an organized, population-based screening program for prostate cancer.

Men who are concerned about their risk of prostate cancer should talk to their primary care provider. Individual decisions to screen should be made as a part of a shared decision-making process involving a discussion between a man and his primary care provider.

2. Why is Cancer Care Ontario making this recommendation?

Systematic reviews of randomized controlled trials of prostate cancer screening using the prostate-specific antigen (PSA) test have shown inconsistent results; some evidence have shown no effect of PSA testing on prostate-cancer mortality while others have shown a small reduction in prostate-cancer mortality. Harms associated with screening, including over-diagnosis and over-treatment, are common.

Cancer Care Ontario will continue to monitor emerging evidence on prostate cancer screening.

3. What impact will Cancer Care Ontario’s recommendations have on a man’s decision to be screened for prostate cancer?

Men in Ontario who are concerned about their risk of prostate cancer should talk to their primary care provider. Individual decisions to screen should be made as a part of a shared decision-making process involving a discussion between a man and his primary care provider.

Discussions about screening decisions should include:

- The man’s risk for prostate cancer, including family history and race
- The risks associated with biopsy and subsequent treatment, if indicated
- The changing landscape of management towards active surveillance for low risk disease
- The man’s general health and life expectancy, and personal preferences

Cancer Care Ontario has developed patient and provider education materials that can be used to support the patient–provider discussions.
4. Are men in Ontario being screened properly?

Given the potential harms of screening, including over-diagnosis and over-treatment, Cancer Care Ontario does not support an organized, population-based screening program for prostate cancer. Men who are concerned about their risk of prostate cancer should talk to their primary care provider. Individual decisions to screen should be made as a part of a shared decision-making process involving a discussion between a man and his primary care provider.

5. Does the Ontario Health Insurance Plan (OHIP) pay for prostate cancer screening using the prostate-specific antigen (PSA) test?

OHIP pays for the PSA test for men who are:

- Receiving treatment for prostate cancer
- Being followed after treatment for prostate cancer
- Suspected of prostate cancer because of their family history and/or the results of their physical exam (including digital rectal examination)

A population-based PSA screening program for men at average risk of prostate cancer is not currently planned by the Ontario Ministry of Health and Long-Term Care. Given the potential harms of screening, including over-diagnosis and over-treatment, Cancer Care Ontario does not support an organized, population-based screening program for prostate cancer.

References:


6. Programs exist for women for breast and cervical cancer. Are men being discriminated against because there is no organized population-based screening program for prostate cancer?

Although there is currently no organized population-based screening program for prostate cancer in Ontario, there are three population-based organized screening programs: ColonCancerCheck, the Ontario Breast Screening Program and the Ontario Cervical Screening Program. The foundation of these organized screening programs is strong scientific evidence demonstrating a reduction in cancer mortality due to screening.

Considerable debate exists about whether the prostate-specific antigen test should be made available (i.e., funded) in Ontario for opportunistic prostate cancer screening in average risk men who follow a shared decision-making process with their doctor.

7. Some organizations and physicians advocate for the use of the prostate-specific antigen test. What should men who are concerned about their risk of prostate cancer do?

Men who are concerned about their risk of prostate cancer should talk to their primary care provider. Individual decisions to screen should be made as a part of a shared decision-making process involving a discussion between a man and his primary care provider.

Discussions about screening decisions should include:
• The man’s risk for prostate cancer, including family history and race
• The risks associated with biopsy and subsequent treatment, if indicated
• The changing landscape of management towards active surveillance for low risk disease
• The man’s general health and life expectancy, and personal preferences

Systematic reviews of randomized controlled trials of prostate cancer screening using the prostate-specific antigen (PSA) test have shown inconsistent results; some evidence have shown no effect of PSA testing on prostate-cancer mortality while others have shown a small reduction in prostate-cancer mortality. Harms associated with screening, including over-diagnosis and over-treatment, are common. Therefore, Cancer Care Ontario does not support an organized, population-based screening program for prostate cancer.

About prostate cancer

8. What is the prostate?

The prostate is a walnut-sized gland just below the bladder. It produces part of the fluid that carries sperm.

9. What is prostate cancer?

Prostate cancer is a malignant tumour that starts in cells of the prostate. A prostate tumour that is malignant can spread, or metastasize, to other parts of the body. However, in most cases, it usually grows slowly and can often be completely removed or managed successfully.

10. What causes prostate cancer?

The causes of prostate cancer are largely unknown, but it is likely that it develops as a result of a complex interplay of genetic and lifestyle factors related to hormones.1

Age and a family history of prostate cancer are the most well established risk factors for prostate cancer, with risk higher among older men and men who have a first-degree relative (i.e., father or brother) who has previously been diagnosed with prostate cancer.1

Ethnicity is also an important risk factor, with prostate cancer incidence rates highest in men of African descent and lowest in Asian men.1

Occupational exposure to arsenic and cadmium2 and diets high in calcium3 are all associated with increased prostate cancer risk, although there is presently not enough evidence to suggest that these are causal factors.

Foods containing lycopene (e.g., tomatoes and tomato products) may protect against prostate cancer; more research is needed to confirm these relationships.3

References:

11. What is the natural history of prostate cancer?

Prostate cancer typically has a long natural history, which means that it grows very slowly and often does not cause harm. Studies have shown that the prevalence of undiagnosed prostate cancer in men at autopsy is high and increases with age (>40 per cent among men aged 40 to 49 years to > 70 per cent among men aged 70 to 79).\(^1\) In some cases, prostate cancer is aggressive, which means it grows quickly and can lead to death. However, within 15 years of diagnosis, most men with prostate cancer die from other competing causes rather than from the prostate cancer itself.\(^2\)

References:


12. Does a prostate cancer diagnosis always require surgery or radiation treatment?

A man who is diagnosed with prostate cancer will not always require surgery or radiation. Treatment options depend on a man’s prostate cancer disease risk (low, intermediate or high). Treatment options may include:

- **Active surveillance** (the cancer is monitored closely with regular tests, and if it progresses, treatment is initiated for curative intent)
- **Radical prostatectomy** (surgery to remove the prostate, seminal vesicles and part of the urethra within the prostate)
- **External beam radiation therapy** (a machine beams radiation, high-energy X-rays or particles, through the skin to the cancer and a small amount of surrounding tissue)
- **Brachytherapy** (radioactive isotope particles are placed in the body in or very close to the cancer cells; this is also called internal radiation therapy)
- **Hormone therapy** (a therapy in which the levels of male hormones, testosterone and dihydrotestosterone are reduced in the body or prevented from reaching the prostate cancer cells)
- **Watchful waiting** (less intensive monitoring of the cancer and initiation of treatment occurring if a man becomes symptomatic)

For more information, Cancer Care Ontario has developed a prostate cancer treatment pathway which is available at [https://www.cancercareontario.ca/sites/ccocancercare/files/assets/DPMProstateTreatment.pdf](https://www.cancercareontario.ca/sites/ccocancercare/files/assets/DPMProstateTreatment.pdf).

13. What are the possible complications associated with a biopsy following a positive or abnormal prostate-specific antigen test?

Men may experience some complications following a prostate biopsy, such as minor bleeding or an exacerbation of urinary symptoms. But these complications are usually minor and resolve spontaneously.\(^1\) In approximately two to four per cent of cases, men will experience a complication requiring hospitalization within 30 days of the biopsy (usually due to an infection).\(^2,3\) Fatal complications are very rare.\(^4\)

References:


About the prostate-specific antigen test

14. What is the prostate-specific antigen (PSA) test?

The PSA test is a blood test that measures the amount of PSA in the blood. PSA is produced by the prostate and is normally present in a man’s blood in small amounts. An elevated PSA level may be an indication that cancer is present. Men who have a prostate infection or prostate growth that is not cancerous (such as benign prostatic hyperplasia, or BPH) may also have high levels of PSA.

15. How accurate is the prostate-specific antigen (PSA) test?

No test is perfect, and this is true of the PSA test.

Since the test is not accurate all the time, there are harms and benefits that can be associated with it and the procedures that may follow it. The test can be elevated in some men who don’t have cancer, creating unnecessary anxiety. It can also miss some cancers in men who do have malignancies, giving them a false sense of security about their health.

Other organizations’ recommendations on prostate cancer screening

16. What do other international and national organizations recommend about prostate-specific antigen (PSA) testing?

Most international and national guidelines and recommendations, including those by the Canadian Task Force on Preventive Health Care (CTFPHC) and the American College of Physicians, recommend against screening for prostate cancer using the PSA test due to the lack of conclusive evidence that prostate cancer screening reduces illness or death associated with this disease. The United States Preventive Services Task Force (USPSTF) recommends individualized decision making about screening for prostate cancer in men ages 55-69 years. Currently, there is not sufficient evidence to suggest a universal benefit to screening.

_Canadian Task Force on Preventive Health Care_¹

The CTFPHC, an agency established by the Public Health Agency of Canada to develop clinical practice guidelines that support primary care providers in delivering preventive health care, published its recommendations on PSA screening (with or without digital rectal examination, or DRE) weighing the possible benefits against potential harms of early diagnosis and treatment of prostate cancer. Based on the lack of convincing evidence that PSA screening reduces prostate cancer mortality, and the consistent evidence that screening and active treatment do lead to harm, the CTFPHC recommended against PSA testing to screen for prostate cancer. More specifically:
• For men younger than 55 years of age and 70 years of age and older, the CTFPHC strongly recommends against screening for prostate cancer with the PSA test. There is no evidence that screening with the PSA test reduces mortality, whereas there is evidence of harms.

• For men aged 55 to 69 years of age, the CTFPHC does not recommend screening for prostate cancer with the PSA test. There is inconsistent evidence of small potential benefits of screening and evidence of harms. This recommendation places a relatively low value on a small potential absolute decrease in prostate cancer mortality, and reflects concerns with false-positive results, unnecessary biopsies, over-diagnosis of prostate cancer and the harms associated with unnecessary treatments.

• For men aged 70 years and older, the CTFPHC strongly recommends against screening for prostate cancer with the PSA test. The recommendation reflects the lower life expectancy and the lack of evidence for benefit of screening this age group, as well as the evidence of harms.

• Groups at increased risk of prostate cancer and dying from it include men of black race and men with a family history of prostate cancer. There are no trial data showing that the benefits or harms of screening differ in these populations compared to men in the general population. However, clinicians may wish to discuss the benefits and harms of screening with men at increased risk of prostate cancer, with explicit consideration of their values and preferences.

For more information, visit the CTFPHC website at https://canadiantaskforce.ca/guidelines/published-guidelines/prostate-cancer/.

United States Preventive Services Task Force

In April 2017, the USPSTF recommended against using the PSA test to screen for prostate cancer in men age 70 and older. For men ages 55 to 69, the USPSTF recommended that the choice to undergo prostate screening should be an individual decision based upon the overall benefits and harms of PSA–based screening. The USPSTF noted that PSA screening can result in a small benefit of reduced mortality due to prostate cancer; however they noted specific harms such as false-positives and over-diagnosis/ over-treatment.

American College of Physicians

In 2013, the American College of Physicians made the following recommendations regarding prostate cancer screening using the PSA test:

• Men between the ages of 50 and 69 years should be informed about the limited potential benefits and substantial harms of screening for prostate cancer.

• The decision to screen using the PSA test should be based on a man’s risk for prostate cancer, a discussion of the benefits and harms of screening, a man's general health and life expectancy, and personal preferences.

• Men who do not express a clear preference for screening should not be screened for prostate cancer using the PSA test.

• Average risk men under the age of 50 years, over the age of 69 years or with a life expectancy of less than 10 to 15 years should not be screened for prostate cancer using the PSA test.

References:

